Our MBC Life

S07 E08 Understanding Progression: How to Identify & Treat ESR1 Mutations in HR+ MBC

SHARE Cancer Support Season 7 Episode 8

Send us a text

New therapeutic options are now available for HR+ MBC.  Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more.